Article

Population pharmacokinetic modeling of tamoxifen and its active metabolite endoxifen in healthy volunteers of African ancestry genotyped for CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5.

2024-11-19

Abstract excerpt

<title>Abstract</title> <p>Purpose Wide inter-individual variability is seen in the clinical outcomes of tamoxifen treatment, which may be attributable to cytochrome P450 genetic polymorphisms. To investigate this, we analysed data from an open-label three parallel arm trial with 36 healthy volunteers of African ancestry to whom a dose of 20 mg of tamoxifen had been administered and drug concentrations of tamoxi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 64aa4cf3-c7d9-50b3-abeb-7416f163ab3e
DOI: 10.21203/rs.3.rs-5381954/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetic modeling of tamoxifen and its active metabolite endoxifen in healthy volunteers of African ancestry genotyped for CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5.DOI 10.21203/rs.3.rs-5381954/v1Read

Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast CancerSemantic proximity Read

Factors Affecting Inter-individual Variability in Endoxifen Concentrations in Patients: Results From the Prospective TOTAM TrialSemantic proximity Read

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifenSemantic proximity Read

Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, EndoxifenSemantic proximity Read

Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balanceSemantic proximity Read

Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.Semantic proximity Read

Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale.Semantic proximity Read

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of TamoxifenSemantic proximity Read

Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.Semantic proximity Read

CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.Semantic proximity Read

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.Semantic proximity Read

Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial.Semantic proximity Read